Sign in

CIK 0001725160

  • Non-accelerated filer
  • Smaller reporting company

Zentalis Pharmaceuticals, Inc.

Sign in to watch
Ticker
ZNTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
823607803
Phone
+1 858-263-4333
Business address
10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
Former names
Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
  1. 4 Shares withheld for taxes Chief Executive Officer gave up 20,655 shares (to pay taxes)
  2. 4 Grant or award Chief Scientific Officer acquired 40,000 shares (grant or award)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Gift Chief Scientific Officer gave 24,158 shares (gift)
  5. 4 Open-market buy Director bought 17,000 shares at $9.88 ($167,943)
  6. 4 Open-market buy Chief Executive Officer bought 5,000 shares at $10.29 ($51,448)
  7. 4 Planned sale Chief Medical Officer sold 10,628 shares at an average $19.50 ($207,298)
  8. 4 Planned sale Chief Scientific Officer sold 6,068 shares at an average $19.50 ($118,355)
  9. 4 Planned sale Chief Financial Officer sold 5,482 shares at an average $19.50 ($106,926)
  10. 4 Planned sale Director sold 5,000 shares at $25.05 ($125,238)
  11. 4 Open-market buy 10% owner bought 4,760,000 shares at $22.66 ($107,861,600)
  12. 4 Grant or award Director acquired 19,059 shares (grant or award)
  13. 4 Grant or award Director acquired 16,364 shares (grant or award)
  14. 4 Grant or award Director acquired 16,364 shares (grant or award)
  15. 4 Planned sale President sold 27,768 shares at an average $26.27 ($729,506)
  16. 4 Planned sale Chief Scientific Officer sold 80,000 shares at $30.02 ($2,401,248)
  17. 4 Grant or award Director acquired 39,732 shares (grant or award)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Grant or award Chief Operating Officer acquired 52,500 shares (grant or award)
  20. 4 Open-market sale Chief Financial Officer sold 7,851 shares at an average $20.13 ($158,005)

Page 4 of 13 · 252 filings